Tryptophanyl tRNA synthetase(WRS) is one of aminoacyl tRNA synthetases and has two forms – full length WRS (FL-WRS) and mini length WRS (mini-WRS, N-truncated form). In vitro study shows that FL-WRS could promptly trigger innate immunity against infection and be released immediately without de novo synthesis. In vivo study shows that WRS increases earlier than other sepsis biomarkers, such as procalcitonin and interleukin-6. Clinical trial shows that (1)WRS is superior to other biomarkers in terms of differentiating sepsis from inflammation, (2)the level of WRS could help to stratify the severity of the septic condition.

• Secreted tryptophanyl-tRNA synthetase as a primary defence system against infection Nature Microbiology 2016 OCT :191
• Clinical value of full-length tryptophanyl-tRNA synthetase for sepsis detection in critically ill patients — A retrospective clinical assessment International Journal of Infection Diseases 2020 May (97):260-66

• Composition and method for detecting a diagnostic marker for infectious disease or infectious complications using tryptophanyl-tRNA synthetase (2016)
  - Korean Patent Registration Completed (10-1771697)
  - U.S./European/Japanese/Chinese patent registration complete
• Antibodies specifically binding to WRS protein and uses thereof (2019)
  - Korean Patent Registration Completed (10-2478445, 10-2489531)
  - US/Europe/Japan/China application completed, under review

1) Curr Opin HIV AIDS. 2010 Nov; 5(6): 463–466.

Complement factor B(CFB) is known to play an important role in the alternative pathway of complement system. JW is underdevelopment of multi-biomarker diagnostic kit using CFB and CA19-9 which pancreatic cancer can be detected in early stage through a simple blood test.

Diagnostic Values of CA 19-9 and CFB According to Cut-off Levels in PC versus Other Disease

¹Sensitivity and specificity of the combination of CFB and CA 19-9 from the maximum Youden’s index.
²Predicted optimal cut-off value from the maximum Youden’s index.
Abbreviations: CA19-9: carbohydrate antigen 19-9; CFB: complement factor b; PC: pancreatic cancer; Others: HD (healthy donor), CP (chronic pancreatitis), HCC (hepatocellular carcinoma), CC (cholangiocarcinoma), GC (gastric cancer)

Identification of Human Complement Factor B as a Novel Biomarker Candidate for Pancreatic Ductal Adenocarcinoma J Proteome Res. 2014 Nov 7;13(11):4878-88

Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role. J Proteome Res. 2021;20(12):5315-5328.

• Pancreatic cancer diagnostic kit including antibody that specifically binds to complement factor B protein (Registration No. 10-1594287)
• Patent registered in KR/EP/JP/CN/US